Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

• Market Cap: €899.09M
• Dividend Yield: 1.16%
• Average Volume (3M): 108.96K
• Price to Earnings (P/E): 22.6
• Beta (1Y): 1.31
• Revenue Growth: 9.64%
• EPS Growth: 35.18%
• Country: DE
• Employees: 1,085
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.14
• Shares Outstanding: 63,515,797
• 10 Day Avg. Volume: 81,969
• 30 Day Avg. Volume: 108,959
• PEG Ratio: 1.06
• Price to Book (P/B): 4.15
• Price to Sales (P/S): 3.13
• P/FCF Ratio: 18.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €22.85
• Price Target Upside: 57.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: €16.50 ▲(13.95% Upside)

Eckert & Ziegler Strahlen und Medizintechnik's overall stock score is driven primarily by its strong financial performance, which is offset by weak technical indicators. The valuation is reasonable, providing some support to the score. The lack of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, positioning the company for sustained expansion.

Balance Sheet Health

A low debt-to-equity ratio reflects prudent financial management, providing flexibility for future investments and growth opportunities.

Profitability

Strong profit margins demonstrate efficient operations and cost management, supporting long-term financial stability and shareholder value.

Negative Factors

Cash Flow Decline

Declining free cash flow growth can limit the company's ability to fund operations and investments, potentially impacting future growth.

Cash Flow Trends

Attention to cash flow trends is advisable as declining trends may affect liquidity and the ability to capitalize on growth opportunities.

Technical Indicators

Weak technical indicators may suggest market skepticism, potentially affecting investor confidence and stock performance in the near term.

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company Description

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) is a leading global provider of isotope technology and medical devices, primarily serving the fields of radiation therapy and nuclear medicine. The company specializes in the development, manufacture, and distribution of high-quality radiopharmaceuticals, medical devices, and components for radiation therapy. With a strong focus on innovation and quality, EUZ plays a crucial role in improving patient care and treatment outcomes in oncology and other medical applications.

How the Company Makes Money

Eckert & Ziegler Strahlen und Medizintechnik generates revenue through the sale of radiopharmaceuticals, medical devices, and components used in radiation therapy and nuclear medicine. Key revenue streams include the production and distribution of isotopes for medical applications, as well as proprietary devices designed for specific treatment protocols. The company benefits from significant partnerships with healthcare providers, research institutions, and pharmaceutical companies, which enhance its market reach and product offerings. Additionally, EUZ engages in research and development activities that not only drive innovation but also open up new markets, contributing to sustained revenue growth.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary

Eckert & Ziegler Strahlen und Medizintechnik exhibits strong financial health with impressive revenue growth and solid profitability metrics. The balance sheet is stable, though rising debt levels warrant attention. Cash flow generation is robust, supporting the company's growth trajectory. Overall, the company is well-positioned in the medical devices industry, but careful management of cost pressures and debt is essential to sustain its financial performance.

Income Statement

Eckert & Ziegler Strahlen und Medizintechnik shows strong revenue growth with a TTM (Trailing-Twelve-Months) growth rate of 94.8%, indicating robust expansion. The company maintains healthy profitability with a gross profit margin of 48.05% and a net profit margin of 11.62%. EBIT and EBITDA margins are also solid at 21.58% and 27.70%, respectively, reflecting efficient operations. However, the slight decline in gross profit margin compared to previous periods suggests potential cost pressures.

Balance Sheet

The balance sheet is stable with a manageable debt-to-equity ratio of 0.25, indicating prudent leverage. Return on equity (ROE) is strong at 14.43%, showcasing effective use of equity capital. The equity ratio stands at 51.16%, reflecting a solid equity base. However, the increase in total debt over recent periods could pose a risk if not managed carefully.

Cash Flow

The company demonstrates strong cash flow generation with a free cash flow growth rate of 8.52% in the TTM period. The operating cash flow to net income ratio is high at 0.93, indicating efficient cash conversion. The free cash flow to net income ratio of 0.74 suggests good cash profitability. Despite these strengths, the volatility in free cash flow growth over the years highlights potential fluctuations in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	304.47M	295.85M	246.09M	222.26M	180.44M	176.14M
Gross Profit	143.86M	143.16M	116.34M	106.78M	91.08M	86.53M
EBITDA	86.16M	77.38M	59.67M	57.90M	56.68M	43.05M
Net Income	39.75M	33.28M	26.30M	29.28M	34.53M	21.29M
Balance Sheet
Total Assets	452.04M	442.40M	439.36M	416.84M	347.73M	292.00M
Cash, Cash Equivalents and Short-Term Investments	121.04M	118.36M	68.00M	82.70M	95.02M	88.61M
Total Debt	46.41M	55.34M	56.30M	49.59M	26.97M	20.40M
Total Liabilities	218.89M	217.18M	215.27M	203.21M	155.20M	143.08M
Stockholders Equity	231.53M	223.45M	222.18M	212.07M	187.39M	147.82M
Cash Flow
Free Cash Flow	44.27M	49.38M	21.12M	3.17M	5.00M	27.88M
Operating Cash Flow	66.48M	66.57M	46.95M	34.30M	33.85M	36.79M
Investing Cash Flow	-32.45M	-16.59M	-42.74M	-41.04M	-23.59M	-13.35M
Financing Cash Flow	-19.79M	-9.99M	-9.28M	-5.71M	-6.06M	-12.96M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.48
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Negative. The current price of 14.48 is below the 20-day moving average (MA) of 15.42, below the 50-day MA of 16.11, and below the 200-day MA of 18.63, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 25.78 is Positive, neither overbought nor oversold. The STOCH value of 3.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EUZ	64 Neutral	€899.09M	22.61	16.93%	1.16%	9.64%	35.18%
BIO3	64 Neutral	€1.34B	-50.72	―	0.13%	-18.82%	-113.85%
FYB	63 Neutral	€418.85M	-2.47	-34.48%	―	-14.84%	-338.52%
COP	60 Neutral	€1.30B	70.07	2.87%	0.20%	1.16%	-43.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BIO	51 Neutral	€1.34B	-58.47	―	―	-18.82%	-113.85%
EVT	38 Underperform	€917.82M	-5.78	-17.98%	―	-2.67%	7.40%